Overview
Individualizing Prostate Cancer Treatment: Special Considerations for Gay and Bisexual Men
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This educational activity features a panel consisting of an oncologist as well as leading experts (a urologist and a researcher) in prostate cancer care considerations in gay and bisexual men (GBM). This panel discusses quality of life considerations and disparities among GBM with prostate cancer. The panel’s aim is to provide clinicians with real-world strategies to facilitate optimal communication and shared decision-making with these patients. This initiative also provides the latest epidemiological and clinical data, controversies, and evolving treatment practices to improve patient-reported outcomes. Additionally, a gay patient shares his prostate cancer story and perspectives to better illustrate and help address the unmet needs that exist among the GBM population. Clinicians need to know the resources out there for GBM with prostate cancer as this minority population is often not focused on in medical education.
This activity is intended for urologists, oncologists, advanced practice providers in specialty practices, specialty nurses, patient navigators, primary care physicians, and other clinicians involved in the care of patients with prostate cancer.
This initiative involves a panel discussion where an expert oncologist serves as a moderator and engages with a leading researcher and urologist on new opportunities to improve outcomes for gay and bisexual men (GBM) with prostate cancer. In addition to the clinical faculty, a gay patient will provide a first-hand testimonial of his prostate cancer treatment experience to better illustrate and personalize the unmet needs. Upon completing this initiative, clinicians will be able to indicate the most recent evidence with sexual disparities in prostate cancer management, evaluate patient-centered tactics to use when choosing therapies for prostate cancer in GBM, and outline the sexual function and sexual bother adverse events the various agents in the prostate cancer armamentarium.
Upon completion of this activity, participants will be able to:
- Outline the latest research relating to sexual disparities in prostate cancer care
- Explain shared decision-making strategies to use when selecting therapies for prostate cancer in GBM
- Describe the sexual function and sexual bother side effects of various prostate cancer treatments and implications for GBM
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sanofi Genzyme, and Merck & Co., Inc..
Channa Amarasekera, MD
Director – Gay and Bisexual Men’s Urology Program
Assistant Professor
Department of Urology
Northwestern Medical Group
Northwestern University Feinberg School of Medicine
Chicago, IL
Director – Gay and Bisexual Men’s Urology Program
Assistant Professor
Department of Urology
Northwestern Medical Group
Northwestern University Feinberg School of Medicine
Chicago, IL
B. R. Simon Rosser, PhD, MPH
Professor, Division of Epidemiology and Community Health
University of Minnesota School of Public Health
Minneapolis, MN
Wenxin (Vincent) Xu, MD
Genitourinary Oncologist and Instructor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
All faculty for this activity, as listed below, have no financial relationships to disclose:
Channa Amarasekera, MD
B. R. Simon Rosser, PhD, MPH
Wenxin (Vincent) Xu, MD
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 1.0 contact hour.
